Company Overview and News

Molson Coors (TAP) Q4 Earnings & Sales Rise Y/Y; Stock Gains

2018-02-14 zacks
Molson Coors Brewing Company (TAP - Free Report) reported fourth-quarter 2017 results, wherein both the top and bottom line improved year over year and the latter also beat the Zacks Consensus Estimate. Further, the company exceeded its cost-savings target for the year, encouraging management to raise its three-year target for 2019. The solid results helped this Zacks Rank #3 (Hold) stock gain 2.7% in the pre-market trading hours.
Upvote Downvote

Molson Coors: Entering The International Market

2017-11-29 seekingalpha
Investment thesis: Molson Coors (NYSE: TAP) shares are at a 52-week low. From my point of view, this is an excellent opportunity to buy a good company operating in a non-cyclical business sector at a low price. The company has shown quite healthy report for the 3 quarter: it actively captures international and Europe markets, improves its balance sheet and looks cheap enough to its closest competitors.
Upvote Downvote

Tracking Allan Mecham's Arlington Value Capital Portfolio - Q3 2017 Update

2017-11-24 seekingalpha
Arlington Value Capital’s 13F portfolio value increased from $874M to $1B. The number of positions increased from 23 to 24.
Upvote Downvote

Molson Coors Brewing Company 2017 Q3 - Results - Earnings Call Slides

2017-11-21 seekingalpha
The following slide deck was published by Molson Coors Brewing Company in conjunction with their 2017 Q3 earnings call.
Upvote Downvote

This Canadian Startup Is Digitizing the Primary Bond Market - Bloomberg

2017-11-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Overall beer market to see lower volumes, but craft to see 5 to 6 percent growth

2017-11-10 cnbc
Craft beer's days of heady double-digit growth may be over, but it is expected to produce volume growth of 5 to 6 percent this year and outperform the broader category, according to a new report.
Upvote Downvote

Molson Coors Brewing (TAP) Q3 2017 Results - Earnings Call Transcript

2017-11-01 seekingalpha
Welcome to the Molson Coors Brewing Company Third Quarter 2017 Earnings Conference Call. Before we begin, I will paraphrase the company's Safe Harbor language. Some of the discussion today may include forward-looking statements. Actual results could differ materially from what the company projects today. So, please refer to its most recent 10-K and 10-Q filings for a more complete description of factors that could affect these projections.
Upvote Downvote

America’s Most Popular Type of Beer Is in Free Fall - WSJ

2017-11-01 wsj
The big three U.S. light-lager brands—Bud Light, Coors Light and Miller Lite—are all losing volume as consumers shift to craft and Mexican import beers as well as to wine and spirits.
Upvote Downvote

Soft U.S. Sales Weigh Upon Molson Coors' (TAP) Q3 Earnings

2017-11-01 zacks
Global brewer Molson Coors Brewing Company (TAP - Free Report) reported third-quarter 2017 results, wherein both top and bottom lines fell year over year and the former also lagged the Zacks Consensus Estimate. However, earnings came in line with the consensus mark, faring better than its three-quarter long trend of posting negative surprise.
Upvote Downvote

Molson Coors (TAP) Meets Q3 Earnings, Sales Miss Estimates

2017-11-01 zacks
Global brewer Molson Coors Brewing Company (TAP - Free Report) came out with third-quarter 2017 results, wherein adjusted earnings of $1.34 per share came in line with the Zacks Consensus Estimate but decreased 3.6% year-over-year.
Upvote Downvote

Molson Coors: Crack Open A Position

2017-10-31 seekingalpha
Molson Coors is one of the largest brewers in the world, and enjoys dominant market shares in the U.S., Canada, the U.K. and Central Europe.
Upvote Downvote

Constellation Breaks Pot Taboo, Opens Door for Major Brands - Bloomberg

2017-10-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Factors Likely to Impact Molson Coors' (TAP) Q3 Earnings

2017-10-26 zacks
Molson Coors Brewing Co (TAP - Free Report) is set to report third-quarter 2017 results before the opening bell on Nov 1.
Upvote Downvote

RPT-GRAPHIC-Stocks to watch as NAFTA's future remains in doubt

2017-10-19 reuters
NEW YORK, Oct 18 (Reuters) - The future of the North American Free Trade Agreement (NAFTA), a nearly 24-year-old trade pact between Canada, the United States and Mexico, hangs in doubt after the latest round of talks in Washington ended in acrimony on Tuesday, casting uncertainty over a range of stocks.
Upvote Downvote

How Constellation Brands’ 2Q18 Earnings Beat Analysts’ Estimates

2017-10-10 marketrealist
Constellation Brands (STZ) delivered adjusted EPS (earnings per share) of $2.47 in fiscal 2Q18, which ended on August 31, 2017. The beer, wine, and spirits producer handily exceeded the consensus Wall Street analysts’ earnings estimate of $2.16 per share. The company has consistently exceeded analysts’ earnings expectations in all the quarters of fiscal 2016 and fiscal 2017 as well as the first two quarters of fiscal 2018.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...